Remarkably, although decitabine reprogramed and enhanced the cytolytic capacity of TCROT-I T cells, after decitabine treatment in vivo,a considerable percentage of CD8+ TILs were not clonal cells, which implied that decitabine might activate some nonantitumor T cells, while the combination of decitabine plus anti–PD-1 precisely promoted the expansion of tumor-specific T cells. This evidence concerns the gene PDCD1 and neoplasm.